Can-Fite BioPharma Commences Phase II Clinical Trial For Additional Indication Of Dry Eye Syndrome

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is progressing through clinical trials for an additional indication of Dry Eye Syndrome. The company announced today that it has commenced patient enrolment in a phase II clinical trial of CF101 for the amelioration of dry eye symptoms. This clinical trial will be conducted in Israel and include 50 patients, who will be treated for 12 weeks at the following 4 medical centers: Assaf Harofeh, Rabin, Sheba and Meir.